Invitrogen Corporation production and diagnostics has announced the introduction of its Invivofectamine™ delivery reagent which enables short interference ribonucleic acid (siRNA) experiments in vivo. The study of RNA interference (RNAi) has revolutionized biology by allowing researchers to directly observe the effects of the loss of function of specific genes in mammalian systems. Using proprietary technology, the Invivofectamine™ delivery reagent allows researchers to directly study the effects of siRNA inside a living organism for a variety of applications, including the drug discovery process.

Invitrogen Corporation, has launched its NCode™ Human and Mouse non-coding RNA microarray. The product is the first high-density microarray that will be used for the purpose of profiling non-coding RNAs. The same array consists of both messenger RNA and non-coding RNA content. Designed by Invitrogen, these arrays are manufactured by Agilent Technologies Inc., with the use of its proprietary SurePrint technology.